Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

ACP InternistIDSA Offers Guidance on Managing Drug Interactions with Nirmatrelvir/Ritonavir

The Infectious Diseases Society of America (IDSA) has issued guidance on managing drug interactions with nirmatrelvir/ritonavir (Paxlovid). Specifically, the IDSA recommends clinicians take six steps to minimize the risk of drug interactions for patients with COVID-19 who are eligible for nirmatrelvir/ritonavir.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form